Xilio Therapeutics Set to Showcase Research at Major Cancer Meeting
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company specializing in immuno-oncology therapies, has announced exciting plans for multiple poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting. This prestigious event will be held at the Gaylord National Convention Center in National Harbor, Maryland, over several days in early November.
The company will highlight significant advancements in their research, including clinical data for their leading therapies, vilastobart and efarindodekin alfa (XTX301). These tumor-activated treatments are designed to enhance immune response against tumors while minimizing systemic side effects often seen in conventional therapies.
Key Poster Presentation Details
Xilio will be unveiling three key poster presentations during the conference:
ctDNA as a Potential Surrogate Biomarker
The first presentation focuses on the potential of circulating tumor DNA (ctDNA) as a surrogate biomarker for assessing responses in heavily pretreated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) undergoing treatment combining vilastobart and atezolizumab. This session is scheduled for Friday, November 7, 2025, and will be presented in the Gaylord Exhibit Halls A & B1.
XTX301 Pharmacodynamic Data
The second presentation will delve into the findings from the first-in-human Phase 1 study of XTX301, an innovative tumor-activated interleukin-12 (IL-12). This groundbreaking therapy demonstrated promising pharmacological effects in patients with advanced solid tumors. Attendees can expect detailed insights on Friday, November 7, 2025, within the same venue.
Masked T Cell Engagers
The third presentation will spotlight the efficacy of masked T cell engagers, which are designed to incite a robust synthetic anti-tumor immunity while ensuring favorable tolerability profiles. This session is set for Saturday, November 8, 2025, in the same exhibit halls, showcasing cutting-edge developments in the field.
The Vision of Xilio Therapeutics
Xilio Therapeutics is dedicated to innovating treatment strategies in cancer therapy. Their goal is to harness tumor-activated molecules that concentrate anti-tumor activity specifically within the tumor microenvironment, which promises improved treatment outcomes while minimizing adverse effects. The company's proprietary platform enables them to push boundaries in immuno-oncology.
As a company striving to improve the quality of life for individuals battling cancer, Xilio's commitment to research excellence and patient-centric approaches remains at the forefront of their mission. These upcoming presentations will serve to reinforce their position as a leader in the development of tumor-activated therapies.
Frequently Asked Questions
What is Xilio Therapeutics focused on?
Xilio Therapeutics specializes in developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes and reducing side effects.
What will Xilio present at the SITC meeting?
Xilio will present clinical data for vilastobart and XTX301, along with findings from their masked T cell engager programs.
When is the SITC 40th Annual Meeting?
The SITC Annual Meeting is scheduled for November 6-9, 2025.
Where will the presentations take place?
The presentations will be held at the Gaylord National Convention Center in National Harbor, Maryland.
How can I learn more about Xilio Therapeutics?
More information about Xilio's initiatives can be found on their official website or through their LinkedIn page for the latest updates and developments.
